Ketogenic Diets May Raise Small Intestine Cancer Risk, Study Suggests

A ketogenic diet—high fat, very low carbohydrate—has become a mainstream strategy for weight loss and metabolic “health.” Yet new mouse research suggests that its effects on cancer may be profoundly tissue-specific, reshaping how we should interpret viral headlines about ketones and tumor protection.

The study, led by researchers at MIT, tested how a ketogenic regimen influences intestinal tumor development in animals predisposed to cancer. Mice received either a ketogenic diet, a standard control diet, or a high-fat/high-calorie diet, allowing the team to separate ketogenic effects from general fat overconsumption.

Results were striking in the small intestine: animals on the ketogenic diet developed significantly more tumors than those on control diets. In fact, tumor rates were similar to or even higher than those observed in the obesogenic high-fat/high-calorie group, despite the ketogenic group not becoming obese.

Mechanistically, the work challenges the idea that circulating ketone molecules are the main drivers. Additional experiments indicated that ketone bodies did not directly govern tumor formation; instead, tumor growth tracked with how intestinal cells metabolize dietary fat for energy.

That fat-burning pathway—fatty acid oxidation—activates PPAR-linked signaling, which increases stem cell proliferation in the intestinal lining. While such proliferation can help tissue repair after injury, the same “growth mode” appears to raise the probability that some proliferating cells transition toward malignancy.

The headline twist arrives when the researchers examine the colon. The ketogenic diet suppressed colon tumor development, echoing earlier reports that ketone-related metabolic shifts can be protective in this region.

Importantly, the new data suggest that colon protection is not mediated by ketone bodies. Rather, the same overall diet triggers opposing outcomes through region-dependent differences in lipid metabolism and stem cell behavior.

The findings carry a practical warning for the booming ketone-supplement market. Because the study attributes both risk and benefit to fat metabolism rather than ketones themselves, ketone drinks may not reproduce either the small-intestine danger or the colon protection observed in mice.

By highlighting how adjacent tissues respond differently to identical dietary inputs, the research suggests ketogenic therapies may need personalization—or at least careful monitoring—before they are broadly applied for cancer prevention or metabolic health.